Search Within

Gary Schwartz

Formats
  1. Journal Article (191)
  2. Meeting Abstract (190)
  3. Conference Paper (3)
  4. Book Section (1)
Groups
  1. Department of Medicine (215)
  2. Solid Tumor Oncology Division (205)
  3. Melanoma Disease Management Team (129)
  4. Center for Pancreatic Cancer Research (99)
  5. Gastrointestinal Oncology Service (99)
  6. GSK Faculty (91)

More Groups

People
  1. David Kelsen (79)
  2. Richard Carvajal (61)
  3. Manish Shah (41)
  4. Mark Dickson (40)
  5. Eileen O'Reilly (36)
  6. Monica Motwani (36)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2018 (2)
  4. 2016 (3)
  5. 2015 (5)
  6. 2014 (23)

More Years

Publications
  1. Journal of Clinical Oncology (103)
  2. Cancer Research (42)
  3. Clinical Cancer Research (39)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (30)
  5. Annals of Oncology (12)
  6. Cancer (12)

More Publications

Publishers
  1. American Association for Cancer Research (121)
  2. American Society of Clinical Oncology (105)
  3. Elsevier Inc. (20)
  4. Springer (20)
  5. Oxford University Press (16)
  6. Wiley Blackwell (15)

More Publishers

Results (385)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A non-randomized phase II study of sequential irinotecan (CPT) and flavopiridol (F) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Abou-Alfa, G. K.; Carvajal, R. D.; Chung, K. Y.; Ghossein, R. A.; Capanu, M.; Gonen, M.; Jacobs, G.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
    Journal Article

    Shah, M. A.; Ramanathan, R. K.; Ilson, D. H.; Levnor, A.; D'adamo, D.; O'reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Measuring tumor response and shape change on CT: Esophageal cancer as a paradigm
    Journal Article

    Schwartz, L. H.; Colville, J. A. C.; Ginsberg, M. S.; Wang, L.; Mazumdar, M.; Kalaigian, J.; Hricak, H.; Ilson, D.; Schwartz, G. K.
    Annals of Oncology (2006)

    Fulltext@MSK | Save
  • Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells
    Journal Article

    Sambol, E. B.; Ambrosini, G.; Geha, R. C.; Kennealey, P. T.; Decarolis, P.; O'Connor, R.; Wu, Y. V.; Motwani, M.; Chen, J. H.; Schwartz, G. K.; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Aurora kinases: New targets for cancer therapy
    Journal Article

    Carvajal, R. D.; Tse, A.; Schwartz, G. K.
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • The Hsp90 inhibitor, 17-Allylamino-17-Demethoxygeldanamycin (17AAG) abrogates the G(2)/M DNA damage checkpoint and induces apoptosis selectively in p53-defective colon cancer cells by down-regulating both Chk1 and Wee1
    Meeting Abstract

    Tse, A. N.; Sheikh, T. N.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Flavopiridol is an active agent in the treatment of gastrointestinal stromal tumor (GIST) cells with relative resistance to imatinib mesylate via both transcriptional suppression and inhibition of autophosphorylation of KIT
    Meeting Abstract

    Sambol, E. B.; Motwani, M.; Ambrosini, G.; Geha, R. C.; Decarolis, P.; O'Connor, R.; Chen, J. H.; Schwartz, G. K.; Singer, Samuel
    Cancer Research (2005)

    Fulltext@MSK | Save
  • A novel Aurora B kinase inhibitor is a potent anticancer agent which induces polyploidy and multinucleation with abnormal chromosomal segregation independent of the p53 status of the cell
    Meeting Abstract

    Nair, J. S.; Tse, A.; Cheema, H.; Ambrosini, G.; Keen, N.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Safingol, an inhibitor of sphingosine kinase, stimulates autophagy in a ceramide-independent and phosphatidylinositol (PI)-3 kinase-mediated manner
    Meeting Abstract

    Coward, J.; Truman, J. P.; Ambrosini, G.; Haimovitz-Friedman, A.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Suberoy1Anilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, induces an aberrant mitotic effect evident by an abnormal bi-polar spindle and abnormal chromosomal segregation, resulting in incomplete cytokinesis of HCT-116 colon cancer cells
    Meeting Abstract

    Cheema, H. S.; Tse, A. N.; Nair, J.; Coward, J.; Ambrosini, G.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save